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Abstract
We evaluated microcalorimetry for real-time susceptibility testing of Aspergillus spp. based on growth-related heat production. The mini-
mal heat inhibitory concentration (MHIC) for A. fumigatus ATCC 204305 was 1 mg/L for amphotericin B, 0.25 mg/L for voriconazole,
0.06 mg/L for posaconazole, 0.125 mg/L for caspofungin and 0.03 mg/L for anidulafungin. Agreement within two 2-fold dilutions between
MHIC (determined by microcalorimetry) and MIC or MEC (determined by CLSI M38A) was 90% for amphotericin B, 100% for vorico-
nazole, 90% for posaconazole and 70% for caspofungin. This proof-of-concept study demonstrated the potential of isothermal microcal-
orimetry for growth evaluation of Aspergillus spp. and real-time antifungal susceptibility testing.
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Abstract
The European Committee on Antimicrobial Susceptibility Testing-Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
has revised the EDef 7.1 document on the method for the determination of broth dilution minimum inhibitory concentrations of anti-
fungal agents for fermentative yeasts. Changes are: dimethylsulphoxide is now the recommended solvent for caspofungin, micafungin
and fluconazole; the shelf-life of plates containing the echinocandins prepared from stock solutions in dimethylsulphoxide is extended to
6 months at )80C; testing of amphotericin and Cryptococcus has been incorporated; and minimum inhibitory concentration ranges for
quality control strains and anidulafungin are included.
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Abstract
The European Committee on Antimicrobial Susceptibility Testing Subcommittee on Antifungal Susceptibility Testing (EUCAST-AFST)
has determined breakpoints for amphotericin B, itraconazole and posaconazole for Aspergillus species. This Technical Note is based on
the EUCAST amphotericin B, itraconazole and posaconazole rationale documents (available on the EUCAST website: http://www.eu-
cast.org/antifungal_susceptibility_testing_afst/rationale_documents_for_antifungals/). The amphotericin B and itraconazole breakpoints
are based on epidemiological cut-off values and clinical experience. The posaconazole breakpoints are also based on pharmacokinetic
and pharmacodynamic data. Breakpoints will be reviewed regularly or when new data emerge.
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